{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:17:36Z","timestamp":1785403056330,"version":"3.56.0"},"reference-count":57,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008207","name":"AstraZeneca Canada Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008207","id-type":"DOI","asserted-by":"crossref"}]},{"id":[{"id":"https:\/\/ror.org\/04n8fbz89","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>To quantify preferences and trade-offs for non-overall survival (OS) endpoints among Canadian adults treated for early-stage cancers, participants completed ten choice sets in a discrete choice experiment. Standard-of-care (SoC) was compared to new treatment profiles defined by five attributes: five-year OS, two-year disease advancement, pathological complete response (pCR), and short- and long-term side effects. SoC attribute levels remained constant across respondents, except OS, which varied. For the new treatment, all attributes except OS (fixed as unknown) varied. Data were analyzed using logistic regression and presented as odds ratios (ORs) with 95% confidence intervals (CIs). Among 103 adults treated for early-stage gastrointestinal (n = 40), breast (n = 32), or lung (n = 31) cancer, median age was 59 (Q1, Q3: 43, 75) years; 46.6% were female. Each 25% decrease in SoC OS was associated with higher odds of choosing the new treatment (OR 3.49; 95% CI 2.82\u20134.31; p &lt; 0.01). Reductions in disease advancement (OR 1.55; 1.26\u20131.91; p &lt; 0.01) and mild or no short-term side effects versus severe (OR 6.67; 4.35\u201310.00) significantly increased selection odds; long-term side effects and pCR showed modest, non-significant influence. When OS data were available for SoC, OS strongly influenced decisions; without OS data for new treatments, participants prioritized disease control and short-term tolerability.<\/jats:p>","DOI":"10.3390\/curroncol33060308","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T08:16:08Z","timestamp":1779783368000},"page":"308","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating Patient Preferences for Clinical Trial Endpoints in Early-Stage Cancer: A Discrete Choice Experiment in Canada"],"prefix":"10.3390","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2884-1167","authenticated-orcid":false,"given":"Alexis T.","family":"Mickle","sequence":"first","affiliation":[{"name":"Broadstreet HEOR, 177 W 7th Ave, Vancouver, BC V5Y 1L8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"Simbulan","sequence":"additional","affiliation":[{"name":"AstraZeneca Canada Inc., 1004 Middlegate Rd, Mississauga, ON L4Y 1M4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Li","sequence":"additional","affiliation":[{"name":"AstraZeneca Canada Inc., 1004 Middlegate Rd, Mississauga, ON L4Y 1M4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0683-8771","authenticated-orcid":false,"given":"Kristoph","family":"Klein-Panneton","sequence":"additional","affiliation":[{"name":"AstraZeneca Canada Inc., 1004 Middlegate Rd, Mississauga, ON L4Y 1M4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4712-1828","authenticated-orcid":false,"given":"Conor L.","family":"Morrison","sequence":"additional","affiliation":[{"name":"Broadstreet HEOR, 177 W 7th Ave, Vancouver, BC V5Y 1L8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0807-8543","authenticated-orcid":false,"given":"Sarah","family":"Walker","sequence":"additional","affiliation":[{"name":"Broadstreet HEOR, 177 W 7th Ave, Vancouver, BC V5Y 1L8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karissa M.","family":"Johnston","sequence":"additional","affiliation":[{"name":"Broadstreet HEOR, 177 W 7th Ave, Vancouver, BC V5Y 1L8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3847-0289","authenticated-orcid":false,"given":"Stephanie","family":"Snow","sequence":"additional","affiliation":[{"name":"QEII Health Sciences Centre, Dalhousie University, 1796 Summer St, Halifax, NS B3H 3A7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"ref_1","unstructured":"Canadian Cancer Society (2025, May 09). Breast Cancer Statistics. Available online: https:\/\/cancer.ca\/en\/cancer-information\/cancer-types\/breast\/statistics."},{"key":"ref_2","unstructured":"Statistics Canada (2024, August 06). Leading Causes of Death, Total Population, by Age Group, Available online: https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1310039401."},{"key":"ref_3","unstructured":"World Health Organization (2023, September 21). Cancer. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cancer."},{"key":"ref_4","unstructured":"BC Cancer (2025, May 09). Breast Cancer Clinical Care Pathway. Available online: http:\/\/www.bccancer.bc.ca\/books\/Documents\/Clinical%20Care%20Pathways\/Breast%20Clinical%20Pathway_Published_V2.pdf."},{"key":"ref_5","unstructured":"BC Cancer (2025, May 09). Gastric\/GEJ Cancer Clinical Care Pathway. Available online: http:\/\/www.bccancer.bc.ca\/books\/Documents\/Clinical%20Care%20Pathways\/Gastric%20Clinical%20Pathway_Published_V1.pdf."},{"key":"ref_6","unstructured":"BC Cancer (2025, May 09). Lung Cancer Clinical Care Pathway. Available online: http:\/\/www.bccancer.bc.ca\/Documents\/Lung%20Clinical%20Pathway_Published.pdf."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"104921","DOI":"10.1016\/j.amsu.2022.104921","article-title":"Neoadjuvant VS adjuvant chemotherapy in patients with locally advanced breast cancer; a retrospective cohort study","volume":"84","author":"Akbari","year":"2022","journal-title":"Ann. Med. Surg."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e000766","DOI":"10.1136\/bmjonc-2025-000766","article-title":"Disease-free survival as a surrogate for overall survival in early-stage pancreatic cancer trials: A correlation meta-analysis","volume":"4","author":"Leite","year":"2025","journal-title":"BMJ Oncol."},{"key":"ref_9","unstructured":"Food and Drug Administation (FDA) (2018). Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics: Guidance for Industry."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1186\/s13063-023-07730-1","article-title":"How is overall survival assessed in randomised clinical trials in cancer and are subsequent treatment lines considered? A systematic review","volume":"24","author":"Royle","year":"2023","journal-title":"Trials"},{"key":"ref_11","first-page":"1121","article-title":"Clinical endpoints in oncology\u2014A primer","volume":"11","author":"Delgado","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"ref_13","unstructured":"Food and Drug Administation (FDA) (2020). Guidance for Industry, Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"lba8000","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA8000","article-title":"Overall survival with neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) in patients with resectable NSCLC in CheckMate 816","volume":"43","author":"Forde","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/jnci\/djx133","article-title":"Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II\u2013III Melanoma Adjuvant Therapy","volume":"110","author":"Suciu","year":"2017","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_16","first-page":"e634","article-title":"What is the difference between overall survival, recurrence-free survival and time-to-recurrence?","volume":"107","author":"Liu","year":"2020","journal-title":"Br. J. Surg."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"865101","DOI":"10.1155\/2015\/865101","article-title":"Which Metrics Are Appropriate to Describe the Value of New Cancer Therapies?","volume":"2015","author":"Johnson","year":"2015","journal-title":"BioMed Res. Int."},{"key":"ref_18","first-page":"10181","article-title":"Beyond Overall Survival: The Value of Oncology- Relevant Endpoints in HTA Body\/Payer Decision-Making","volume":"8","author":"Geissler","year":"2023","journal-title":"J. Oncol. Res. Ther."},{"key":"ref_19","first-page":"S5","article-title":"Looking beyond survival data: How should we assess innovation in oncology reimbursement decision making","volume":"9","author":"Fameli","year":"2023","journal-title":"Value Outcomes Spotlight"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.4103\/ijc.IJC_1417_20","article-title":"Significance of emerging clinical oncology endpoints in support of overall survival","volume":"59","author":"Patil","year":"2022","journal-title":"Indian J. Cancer"},{"key":"ref_21","unstructured":"Aitken, M., Longosz, A., Malde, R., Ladha, S., Chow, I., and Wagner, P. (2021). Evolving Oncology Endpoints: A New Horizon for Oncology Outcomes, IQVIA Institute."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Szabo, S.M., Walker, S., Griffin, E., McMillan, A., Bick, R., Simbulan, F., Ting, E., and Snow, S. (2025). \u201cAre You Just Looking to \u2018Survive\u2019?\u201d: A Qualitative Study of Importance of Oncology Endpoints Beyond Overall Survival in Early-Stage Cancer. Cancers, 17.","DOI":"10.3390\/cancers17193260"},{"key":"ref_23","first-page":"657","article-title":"Patients\u2019 preferences: A discrete-choice experiment for treatment of non-small-cell lung cancer","volume":"16","author":"Bethge","year":"2014","journal-title":"Eur. J. Health Econ."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2381468319855386","DOI":"10.1177\/2381468319855386","article-title":"The Value of Progression-Free Survival in Metastatic Breast Cancer: Results From a Survey of Patients and Providers","volume":"4","author":"MacEwan","year":"2019","journal-title":"MDM Policy Pract."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1377\/hlthaff.2011.1300","article-title":"How Cancer Patients Value Hope And The Implications For Cost-Effectiveness Assessments Of High-Cost Cancer Therapies","volume":"31","author":"Lakdawalla","year":"2012","journal-title":"Health Aff."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1586\/14737167.2013.814948","article-title":"Does framing of cancer survival affect perceived value of care? A willingness-to-pay survey of US residents","volume":"13","author":"Lin","year":"2013","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"23814683251372622","DOI":"10.1177\/23814683251372622","article-title":"Patient Preferences in Neoadjuvant Therapy for HER2+ Early-Stage Breast Cancer","volume":"10","author":"Batchelder","year":"2025","journal-title":"MDM Policy Pract."},{"key":"ref_28","first-page":"3","article-title":"Five-year cancer survival by stage at diagnosis in Canada","volume":"34","author":"Ellison","year":"2023","journal-title":"Health Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1056\/NEJMoa0810818","article-title":"Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer","volume":"361","author":"Mouridsen","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_30","unstructured":"Cancer Care Ontario (2025, May 08). Immune Checkpoint Inhibitor Toxicity Management Clinical Practice Guideline. Available online: https:\/\/www.cancercareontario.ca\/en\/guidelines-advice\/types-of-cancer\/52976."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1634\/theoncologist.12-S1-4","article-title":"Cancer-Related Fatigue: The Scale of the Problem","volume":"12","author":"Hofman","year":"2007","journal-title":"Oncologist"},{"key":"ref_32","unstructured":"Hahn, G., and Shapiro, S. (1966). A Catalog and Computer Program for the Design and Analysis of Orthogonal Symmetric and Asymmetric Fractional Factorial Experiments, General Electric Corporation."},{"key":"ref_33","unstructured":"Orme, B. (2020). Getting Started with Conjoint Analysis: Strategies for Product Design and Pricing Research, Research Publishers LLC."},{"key":"ref_34","unstructured":"(2017, May 10). Qualtrics Software. Available online: https:\/\/www.qualtrics.com."},{"key":"ref_35","unstructured":"Egnyte, I. (2026, May 07). Egnyte Connect. Available online: https:\/\/www.egnyte.com\/."},{"key":"ref_36","unstructured":"WCG IRB (2026, May 05). IRB Review Solutions. Available online: https:\/\/www.wcgclinical.com\/solutions\/irb-review\/."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s40273-024-01431-6","article-title":"A Reporting Checklist for Discrete Choice Experiments in Health: The DIRECT Checklist","volume":"42","author":"Ride","year":"2024","journal-title":"PharmacoEconomics"},{"key":"ref_38","unstructured":"R Core Team (2026, May 07). R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. Available online: https:\/\/www.r-project.org\/."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/S1470-2045(24)00596-5","article-title":"Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: A discrete choice experiment","volume":"25","author":"Forrest","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1093\/oncolo\/oyad064","article-title":"Patient Understanding of Oncology Clinical Trial Endpoints in Direct-to-Consumer Television Advertising","volume":"28","author":"Sullivan","year":"2023","journal-title":"Oncologist"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/cncr.32730","article-title":"Patient familiarity with, understanding of, and preferences for clinical trial endpoints and terminology","volume":"126","author":"Railey","year":"2020","journal-title":"Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1002\/cncr.30494","article-title":"Discussing molecular testing in oncology care: Comparing patient and physician information preferences","volume":"123","author":"Pinheiro","year":"2017","journal-title":"Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1055\/s-0042-101025","article-title":"Targets for Neoadjuvant Therapy\u2014The Preferences of Patients with Early Breast Cancer","volume":"76","author":"Thill","year":"2016","journal-title":"Geburtshilfe Frauenheilkd."},{"key":"ref_44","first-page":"149","article-title":"Patient preferences in choosing chemotherapy regimens for advanced non-small cell lung cancer","volume":"3","author":"Dubey","year":"2005","journal-title":"J. Support. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2147\/IJWH.S31331","article-title":"Patient preferences for chemotherapies used in breast cancer","volume":"4","author":"Beusterien","year":"2012","journal-title":"Int. J. Women\u2019s Health"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1016\/j.jval.2022.05.003","article-title":"How Do Treatment Preferences of Patients With Cancer Compare With Those of Oncologists and Family Members? Evidence From a Discrete Choice Experiment in China","volume":"25","author":"Zhang","year":"2022","journal-title":"Value Health"},{"key":"ref_47","unstructured":"Matthius, A., and Quinn, E. (2025, May 09). Experts Forecast Cancer Research and Treatment Advancements in 2025. Available online: https:\/\/www.aacr.org\/blog\/2025\/01\/10\/experts-forecast-cancer-research-and-treatment-advances-in-2025\/."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e2457020","DOI":"10.1001\/jamanetworkopen.2024.57020","article-title":"Understanding of Clinical Trials Among Patients With Cancer and Their Relatives","volume":"8","author":"Tolunay","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e13520","DOI":"10.1200\/JCO.2024.42.16_suppl.e13520","article-title":"Barriers to accessing cancer care from patients\u2019 perspective: A single cancer center experience","volume":"42","author":"Patel","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1200\/EDBK_156686","article-title":"The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies","volume":"35","author":"Unger","year":"2016","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jval.2014.01.002","article-title":"Discrete Choice Experiment to Estimate Breast Cancer Patients\u2019 Preferences and Willingness to Pay for Prophylactic Granulocyte Colony-Stimulating Factors","volume":"17","author":"Johnson","year":"2014","journal-title":"Value Health"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.jpainsymman.2019.01.016","article-title":"The Stability of Treatment Preferences Among Patients With Advanced Cancer","volume":"57","author":"Jabbarian","year":"2019","journal-title":"J. Pain Symptom Manag."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"S334","DOI":"10.1016\/j.jval.2023.09.1766","article-title":"HTA82 Surrogate Measures and the Health Technology Assessment of Cancer Drugs in Ireland: A Retrospective Analysis of EMA Cancer Drug Indication Approvals Between 2017 and 2022 and Recommendations Made By the NCPE in Ireland","volume":"26","author":"Assi","year":"2023","journal-title":"Value Health"},{"key":"ref_54","unstructured":"Food and Drug Administration (FDA) (2026, April 30). CDER Drug and Biologic Accelerated Approvals Based on a Surrogate Endpoint, Available online: https:\/\/www.fda.gov\/media\/151146\/download."},{"key":"ref_55","unstructured":"European Medicines Agency (EMA) (2023). Guideline on the Clinical Evaluation of Anticancer Medicinal Products, EMA."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e70445","DOI":"10.1111\/cts.70445","article-title":"Surrogate Endpoints in Regulatory Decision-Making","volume":"18","author":"Jeng","year":"2025","journal-title":"Clin. Transl. Sci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s40271-015-0118-z","article-title":"Sample Size Requirements for Discrete-Choice Experiments in Healthcare: A Practical Guide","volume":"8","author":"Donkers","year":"2015","journal-title":"Patient\u2014Patient-Centered Outcomes Res."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/6\/308\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T04:17:53Z","timestamp":1779941873000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/6\/308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":57,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["curroncol33060308"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33060308","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]}}}